Hip & pelvis

  • 제21권1호
  • /
  • Pages.6-16
  • /
  • 2009
  • /
  • 2287-3260(pISSN)
  • /
  • 2287-3279(eISSN)
대한고관절학회 (The Korean Hip Society)
권호 표지

골다공증의 병인 및 골다공증 골절의 예방

Osteoporosis: Pathogenesis and Fracture Prevention

  • 임영욱 (가톨릭대학교 의과대학 강남성모병원 정형외과) ;
  • 선두훈 (대전선병원 정형외과) ;
  • 김용식 (가톨릭대학교 의과대학 강남성모병원 정형외과)
  • 발행 : 2009.03.31

⟨ 이전 논문 다음 논문 ⟩

초록

키워드

참고문헌

  1. Archer DF, Hendrix S, Gallagher JC, et al.: Endometrial effects of tibolone. J Clin Endocriol Metab, 92: 911-918, 2007. https://doi.org/10.1210/jc.2006-2207
  2. Barrett-Connor E, Mosca L, Collins P, et al.: Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med, 355: 125-137, 2006. https://doi.org/10.1056/NEJMoa062462
  3. Black DM, Bilezikian JP, Ensrud KE, et al.: One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med, 353: 555-565, 2005. https://doi.org/10.1056/NEJMoa050336
  4. Cooper C, Campion G, Melton LJ: Hip fractures in the elderly: a world-wide projection. Osteoporos Int, 2: 285- 289, 1992. https://doi.org/10.1007/BF01623184
  5. Grisso JA, Kelsey JL, Strom BL, et al.: Risk factors for falls as a cause of hip fracture in women. The Northeast Hip Fracture Study Group. N Eng J Med, 324: 1326-1331, 1991. https://doi.org/10.1056/NEJM199105093241905
  6. Johnell O, Kanis JA: An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int, 17: 1726-1733, 2006. https://doi.org/10.1007/s00198-006-0172-4
  7. Karlsson MK, Gerdhem P, Ahlborg HG: The prevention of osteoporotic fractures. J Bone Joint Surg, 87-B: 1320-1327, 2005. https://doi.org/10.1302/0301-620X.87B10.16578
  8. McAughey JM, McAdoo M: Hip protectors. Acceptability of hip protectors was 35% at six months in the community. BMJ, 324: 1454, 2002. https://doi.org/10.1136/bmj.324.7351.1454
  9. McClung M: Role of RANKL inhibition in osteoporosis. Arthritis Res Ther. 9 Suppl 1: S3, 2007.
  10. Rogers MJ: New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des, 9(32): 2643-2658, 2003. https://doi.org/10.2174/1381612033453640
  11. Rossouw JE, Prentice RL, Manson JE, et al.: Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA, 297: 1465-1477, 2007. https://doi.org/10.1001/jama.297.13.1465
  12. Russell RG, Xia Z, Dunford JE, et al.: Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann NY Acad Sci, 1117: 209-257, 2007. https://doi.org/10.1196/annals.1402.089
  13. Singer AJ, Boonen S: Osteoporosis management: translating research into optimal fracture protection II. Curr Med Res Opin, 24: 1789-1796, 2008. https://doi.org/10.1185/03007990802115887
  14. The Korean Society of Bone Metabolism: Diagnosis and Treatment of osteoporosis. 1-5, 2008.
  15. The Korean Society of Bone Metabolism: Diagnosis and Treatment of osteoporosis. 35-88, 2008.
  16. Wolf SL, Barnhart HX, Kutner NG, McNeely E, Coogler C, Xu T: Reducing frailty and falls in older persons: an investigation of Tai Chi and computerized balance training. Atlanta FICSIT Group. Frailty and Injuries: Cooperative Studies of Intervention Techniques. J Am Geriatr Soc, 44: 489-497, 1996.
  17. http://www.nof.org/professionals/NOF_CLinicians_Guide.pdf